Sudeep Pharma revenue climbs 28%, but project delays and working capital bite
FY26 profits hit ₹174.3 cr as management battles energy-linked commissioning delays at its Nandesari facility.
— 2 earlier stories on Sudeep Pharma Ltd. →What's new
- Annual revenue reached ₹642.6 cr, up 27.9%; PAT rose 25.6% to ₹174.3 cr.
- LPG and energy shortages pushed back the Nandesari greenfield facility launch.
- Management targets 37-38% margins by FY27-28 and expects 2,500 metric tons of battery material output in FY27.
Why it matters
The jump in working capital days to 213 is a glaring red flag that offsets the headline growth. Sudeep Pharma’s ability to hit its April 2027 battery materials deadline now depends entirely on securing the energy supply that currently stalls its Nandesari plant.
What we're watching
- Any further slippage in the Nandesari facility timeline due to energy shortages.
- Progress in reducing working capital days toward historical norms.
- Conversion of the 700 metric tons of battery material orders into revenue.
The full read
Sudeep Pharma’s FY26 results show a company in rapid expansion, with revenue climbing 27.9% to ₹642.6 crore and profit reaching ₹174.3 crore. Yet, the growth comes with friction. A working capital cycle that has ballooned to 213 days from 184 indicates that cash is getting stuck somewhere in the pipeline. Management blames recent commissioning delays at the Nandesari greenfield facility on acute LPG and energy shortages. While the company is looking ahead to a 37-38% margin profile by FY27-28, it must first navigate these persistent supply-chain bottlenecks. The battery materials business is the next big bet, with 700 metric tons of orders already in hand and 42 customers engaged. Phase 1 commissioning remains set for April 2027, with a target of 2,500 metric tons in FY27. Whether these targets hold depends on energy stability. The current liquidity strain makes that a high-stakes test.